Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMS-986458 + mosunetuzumab
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
**BMS-986458 + mosunetuzumab** is an investigational combination therapy comprised of two components: BMS-986458, an orally available, highly selective cereblon (CRBN) E3 ubiquitin ligase-dependent heterobifunctional ligand-directed degrader of B-cell lymphoma 6 (BCL6), and mosunetuzumab, a bispecific monoclonal antibody that engages CD3 on T cells and CD20 on B cells to redirect T cells for targeted B-cell lymphoma cell lysis. BMS-986458 acts by degrading BCL6 to induce anti-tumor activity and upregulate CD20 expression, while mosunetuzumab functions as a T-cell engager facilitating immune-mediated clearance of malignant B cells. This combination is under investigation for the treatment of relapsed or refractory non-Hodgkin lymphoma in clinical trials, aiming to offer a chemotherapy-free regimen for B-cell malignancies[2][4].
- Other names
- BMS-986458 + LunsumioBMS-986458 + mosunetuzumab
02
Targets
CD3 (T-cell surface glycoprotein CD3)CD20 (B-lymphocyte antigen CD20)CRBN (Cereblon)BCL6 (B cell lymphoma 6 protein)
Beyond the preview
Go deeper on BMS-986458 + mosunetuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMS-986458 + mosunetuzumab.